VVOS files Form 8-K, furnishes Q3 2025 financial results press

Rhea-AI Filing Summary

Vivos Therapeutics, Inc. filed a Form 8-K to report that it released its financial results for the third quarter ended September 30, 2025. On November 19, 2025, the company issued a press release detailing these results, which is furnished as Exhibit 99.1 to the report and incorporated by reference. The company notes that this information, including Exhibit 99.1, is being furnished rather than filed, which limits certain liability and incorporation implications under securities laws.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001716166 0001716166 2025-11-19 2025-11-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 19, 2025

Vivos Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-39796		81-3224056
(State or other jurisdiction		(Commission		(I.R.S. Employer
of incorporation)		File Number)		Identification No.)

7921 Southpark Plaza, Suite 210

Littleton, Colorado 80120

(Address of principal executive offices) (Zip Code)

(866) 908-4867

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		VVOS		The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On November 19, 2025, Vivos Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release of the Company, dated November 19, 2025 announcing its financial results for the third quarter ended September 30, 2025.
104		Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	VIVOS THERAPEUTICS, INC.
Dated: November 19, 2025	By:	/s/ Bradford Amman
	Name:	Bradford Amman
	Title:	Chief Financial Officer

FAQ

What did Vivos Therapeutics (VVOS) announce in this Form 8-K?

Vivos Therapeutics (VVOS) reported that on November 19, 2025 it issued a press release announcing its financial results for the third quarter ended September 30, 2025, furnished as Exhibit 99.1.

Which period do the VVOS financial results in this 8-K cover?

The financial results announced by Vivos Therapeutics in this Form 8-K cover the third quarter ended September 30, 2025.

How are the VVOS Q3 2025 results presented in the Form 8-K?

The Vivos Therapeutics Q3 2025 results are presented through a press release that is furnished as Exhibit 99.1 to the Form 8-K and incorporated by reference.

Are the VVOS Q3 2025 results considered "filed" with the SEC?

No. Vivos Therapeutics states that the information in this Form 8-K, including Exhibit 99.1, is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.

Who signed the Vivos Therapeutics (VVOS) Form 8-K for the Q3 2025 results?

The Form 8-K was signed on behalf of Vivos Therapeutics, Inc. by Bradford Amman, the company’s Chief Financial Officer.

What exhibits are included with the Vivos Therapeutics Q3 2025 Form 8-K?

The Form 8-K includes Exhibit 99.1, the press release dated November 19, 2025 announcing Q3 2025 financial results, and Exhibit 104, the Cover Page Interactive Data File in iXBRL format.